Biomerica (BMRA) Cash & Equivalents (2010 - 2026)

Biomerica's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 56.31% year-over-year to $1.3 million; the TTM figure through Feb 2026 stood at $1.3 million (down 56.31% YoY), while the FY2025 annual figure was $3.1 million, down 26.67% from the prior year.
• Cash & Equivalents came in at $1.3 million for Q1 2026 at Biomerica, down from $2.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.2 million in Q1 2022 to a low of $1.3 million in Q1 2026.
• A 5-year average of $4.9 million and a median of $4.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 92.96% in 2022 and sank 67.12% in 2023, its largest moves.
• Biomerica's Cash & Equivalents stood at $5.1 million in 2022, then surged by 40.81% to $7.1 million in 2023, then slumped by 66.75% to $2.4 million in 2024, then increased by 7.21% to $2.5 million in 2025, then tumbled by 47.46% to $1.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.3 million, $2.5 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison